Expert consensus paper on the use of Vedolizumab for the management of patients with moderate-to-severe Inflammatory Bowel Disease.

Alessandro Armuzzi, Paolo Gionchetti, Marco Daperno, Silvio Danese, Ambrogio Orlando, Maria Lia Scribano, Maurizio Vecchi, Fernando Rizzello, Sandro Ardizzone, Fabiana Castiglione, Massimo Fantini, Gionata Fiorino, Giuseppe Frieri, Luca Neri, Maria Lia Scribano, Giacomo Carlo Sturniolo

Risultato della ricerca: Contributo in rivistaArticolo in rivista

31 Citazioni (Scopus)

Abstract

Crohn's Disease (CD) and Ulcerative Colitis (UC) are chronic, relapsing conditions resulting from uncontrolled inflammation of the intestinal mucosa. Both conditions are associated with significant disability and patients with CD face higher mortality rates compared to the general population. The increasing understanding of the immunological basis of the disease led to the introduction of biologic therapies targeting key pathways of the natural and adaptive immune response such as Tumor Necrosis Factor α (TNF-α) inhibitors and, more recently, integrin-receptor antagonists. Treatment with TNF-α inhibitors improved clinical and patient-reported outcomes for many patients who did not benefit from conventional therapy. However, a sizeable share of patients still face suboptimal outcomes due to primary or secondary therapy failure. With the introduction of VDZ, a biologic treatment targeting novel IBD-relevant biologic pathways, it is crucial to understand how to integrate such innovations into current clinical practice. To this end, a panel of 14 Italian experts in the management of IBD met for a roundtable discussion. Recommendations concerning the management of moderate-to-severe IBD based on experts' opinions and literature review are discussed in the present report.
Lingua originaleEnglish
pagine (da-a)360-370
Numero di pagine11
RivistaDIGESTIVE AND LIVER DISEASE
DOI
Stato di pubblicazionePubblicato - 2016

Keywords

  • Vedolizumab
  • inflammatory bowel disease

Fingerprint

Entra nei temi di ricerca di 'Expert consensus paper on the use of Vedolizumab for the management of patients with moderate-to-severe Inflammatory Bowel Disease.'. Insieme formano una fingerprint unica.

Cita questo